First Tracks Biotherapeutics Shares Rise 9% On Positive Celiac Disease Trial Data

First Tracks Biotherapeutics (TRAX) shares rose 9% after positive Phase 1b trial results for ANB033 in celiac disease treatment. The stock is up $2.92 to $34.77 on Nasdaq.

Original reporting
Published Oct 12, 2026, 5:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$TRAX
Bullish
high confidence
Mentioned
$TRAX
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$TRAXBullishHigh
01

Why it matters

The announcement triggered a 9% share price increase, indicating strong market reaction to early‑stage clinical success.

02

Market read

Positive early‑stage data can catalyze further buying, especially in a sector sensitive to trial outcomes.

03

What to watch

Potential regulatory hurdles and competition from other celiac therapies may temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

First Tracks Biotherapeutics announced Phase 1b data showing protection against gluten‑induced damage in celiac disease patients.

Company-level read

Ticker impact

$TRAXBullishHigh confidence
Context

First report of positive Phase 1b trial data for ANB033, driving a 9% intraday stock rise.

Expected impact

upward pressure as market absorbs encouraging clinical data

Evidence & confidence

The data is new, material for a biotech, and the stock already jumped 9% on the news.

Market effects

Boosts sentiment for the broader biotech/clinical‑trial sector.

Positive for U.S. biotech listings on Nasdaq.

Limited to investors tracking biotech pipelines worldwide.

Counterpoint

Trial is Phase 1b; success does not guarantee later-stage results, caution on over‑optimism.

Key entities

  • First Tracks Biotherapeutics

    Nasdaq‑listed biotech developing celiac disease therapies.

  • ANB033

    Experimental therapy evaluated in Phase 1b trial.

Related articles

$TRAXHighAI 8/10

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

$TRAXMedAI 8/10

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.